ethyl 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butanoate | 904689-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: ethyl 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butanoate
• 英文别名: Ethyl 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butanoate
• CAS: 904689-62-9
• 化学式: C₁₆H₂₂Cl₂N₂O₂
• 分子量: 345.269
• InChiKey: SCPLNVCUUNCOBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents
  申请人：Bhat Laxminarayan

  公开号：US20090298819A1

  公开（公告）日：2009-12-03

  The present invention provides novel piperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.

  本发明提供了一种新颖的哌嗪衍生物，可以优势地用于治疗精神分裂症和相关精神病，如急性躁狂、双相情感障碍、自闭症和抑郁症。
• Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents
  申请人：Bhat Laxminarayan

  公开号：US20080293736A1

  公开（公告）日：2008-11-27

  The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.

  本发明提供了新型喹诺酮衍生物，可以有效用于治疗精神分裂症及相关精神病，如急性躁狂症、双相情感障碍、自闭症和抑郁症。
• COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES
  申请人：Bhat Laxminarayan

  公开号：US20100222359A1

  公开（公告）日：2010-09-02

  The present invention provides quinazolinedione derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, depression and dementia.

  本发明提供了喹唑啉二酮衍生物，可优势地用于治疗精神分裂症和相关精神病，如急性躁狂、双相障碍、自闭症、抑郁症和痴呆症。
• COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS
  申请人：Reviva Pharmaceuticals, Inc.

  公开号：EP2162135A1

  公开（公告）日：2010-03-17
• COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS
  申请人：Reviva Pharmaceuticals, Inc.

  公开号：EP2299814A1

  公开（公告）日：2011-03-30